For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 0 | 22,270,465 | ||
| Research and development | 84,454,595 | 49,968,585 | ||
| General and administrative | 23,687,535 | 14,866,722 | ||
| Total operating expenses | 108,142,130 | 64,835,307 | ||
| Loss from operations | -108,142,130 | -42,564,842 | ||
| Other income | 45,421 | 7,471 | ||
| Investment income | 6,257,607 | 2,202,990 | ||
| Interest expense | 3,045,725 | - | ||
| Loss on disposal of fixed assets | -157,519 | -112,805 | ||
| Total other income (expense) | 3,099,784 | 2,097,656 | ||
| Loss before income taxes | -105,042,346 | - | ||
| (provision for) benefit from income taxes | 1,600 | - | ||
| Net loss | -105,043,946 | -40,467,186 | ||
| Net unrealized gain (loss) on marketable securities | -743,801 | 791,142 | ||
| Comprehensive loss | -105,787,747 | -39,676,044 | ||
| Basic EPS | -2.26 | -1.15 | ||
| Diluted EPS | -2.26 | -1.15 | ||
| Basic Average Shares | 46,478,416 | 35,218,628 | ||
| Diluted Average Shares | 46,478,416 | 35,218,628 | ||
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)